BAY x 3702. Neuroprotectant, 5-HT(1A) agonist

Drugs of the Future

Volumn 22, Issue 4, 1997, Pages 341-349

  De Vry, Jean ^a   Dietrich, Hartmut ^a   Glaser, Thomas ^b   Heine, Hans Georg ^b   Horváth, Ervin ^a   Jork, Reinhard ^a   Maertins, Thomas ^b   Mauler, Frank ^a   Opitz, Wolfgang ^a   Scherling, Dietrich ^b   Schohe Loop, Rudolf ^b   Schwarz, Thomas ^b  

^a MEDA Manufacturing GmbH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALBUMIN; ALPHA1 GLYCOPROTEIN; CALCIUM ION; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; REPINOTAN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ARTICLE; BRAIN INJURY; CALCIUM TRANSPORT; CELL MEMBRANE DEPOLARIZATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN;

EID: 0030814402     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Junge, B., Schohe, R., Seidel, P.-R. et al. (Bayer AG). Substd. amino methyl tetralines, and their heterocyclic analogous cpds. EP 352613.
2. Wolf, P.A. An overview of the epidemiology of stroke. Stroke 1990, 21(Suppl. II): 4-6.
3. Sacco, R.L. Frequency and determinants of stroke. In: Clinical Atlas of Cerebrovascular Disease, M. Fisher (Ed.), Mosby-Year Book Europe, London, 1994, 1.1-1.16.
4. Dunn, C.D.R. Stroke: Trends, treatments and markets. Scrip Reports, PJB Publications, Richmond, 1995.
5. Jagger, J., Levine, J.I., Jane, J.A. et al. Epidemiologic features of head injury in predominantly rural population. J Trauma 1984, 24: 40-4.
6. Kalsbeek, W.D., McLaurin, R.L., Harris, B.S. et al. The national head and spinal cord injury survey: Major findings. J Neurosurg 1980, 53: 19-31.
7. Jennet, B., Frankowski, R.F. The epidemiology of head injury. In: Handbook of Clinical Neurology, R. Braakman (Ed.), Elsevier, New York, 1990, 1-16.
8. Benveniste, H. The excitotoxin hypothesis in relation to cerebral ischemia. Cerebrovasc Brain Metab Rev 1991, 3: 213-45.
9. Sarna, G.S., Obrenovitch, T.P., Matsumoto, T. et al. Evidence of a differential sensitivity of monoamines neurotransmission to ischemia: An intracerebral dialysis study. J Neurochem 1990, 55: 937-40.
10. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1: 623-34.
11. Rothman, S.M., Olney, J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986, 19: 105-11.
12. Butcher, S.P., Bullock, R., Graham, D.I., McCulloch, J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 1990, 21: 1727-33.
13. Siesjö, B.K. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J Neurosurg 1992, 77: 169-84.
14. Siesjö, B.K. Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanism of damage and treatment. J Neurosurg 1992, 77: 337-54.
15. Meyer, F.B. Calcium, neuronal hyperexcitability and ischemic injury. Brain Res Rev 1989, 14: 227-43.
16. Choi, D.W. Excitotoxicity. In: Excitatory Amino Acid Antagonists, B.S. Meldrum (Ed.), Blackwell, Oxford, 1991, 216-36.
17. 1A Receptors in Depression and Anxiety, S.M. Stahl, M. Gastpar, J.M. Keppel Hesselink and J. Traber (Eds.), Raven Press, New York, 1992, 35-53.
18. 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology 1995, 121: 1-26.
19. 1A receptors in psychopathology and the mechanism of action of clinically effective therapeutic agents. Drug News Perspect 1996, 9: 270-80.
20. 1A agonists. Curr Opin Invest Drugs 1993, 4: 205-13.
21. 1A receptors in the rat hippocampus and cortex. Drug Dev Res 1992, 26: 275-86.
22. Colino, A., Halliwell, J.V. Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin Nature 1987, 328: 73-7.
23. Davies, M.F., Deisz, R.A., Prince, D.A., Peroutka, S.J. Two distinct effects of 5-hydroxytriptamine on single cortical neurons. Brain Res 1987, 423: 347-52.
24. 1-like receptors on glutamatergic terminals inhibit N-methyl-D-aspartate-induced cyclic GMP production in rat cerebellar slices. J Pharmacol Exp Ther 1991, 257: 1184-8.
25. 1A receptor agonists on the glutamate-induced rise in cytosolic calcium concentration as well as on calcium and potassium currents in hippocampal neurons. In: Pharmacology of Cerebral Ischemia, J. Kriegelstein and H. Oberpichler-Schwenk (Eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1994, 89-97.
26. 1A receptors in guinea pig dentate gyrus. Brain Res 1996, 728: 175-80.
27. 1A agonists: A new therapeutic principle for stroke treatment. Stroke 1990, 21(Suppl. IV): 161-3.
28. 1A agonists show neuroprotectant activity in rats and mice. Eur J Pharmacol 1990, 183: 1953-4.
29. 1A agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 1990, 21(Suppl. IV): 164-6.
30. 1A receptor agonists as neuroprotective agents in cerebral ischemia. In: Pharmacology of Cerebral Ischemia, J. Krieglstein and H. Oberpichler (Eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1990, 485-91.
31. 1A receptor agonists and neuroprotection. In: Serotonin: From Cell Biology to Pharmacology and Therapeutics, P.M. Vanhoutte and R. Paoletti (Eds.), Kluwer Academic Publishers, Boston, 1993, 401-5.
32. 1A-agonist CM57493 on infarct area, infarct volume and hippocampal neuronal damage after focal and global cerebral ischemia in mice and rats. In: Pharmacology of Cerebral Ischemia, J. Krieglstein and H. Oberpichler (Eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1990, 493-7.
33. 1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol 1991, 203: 213-22.
34. Prehn, J.H.M., Welsch, M., Backhauss, C. et al. Effects of serotonergic drugs in experimental brain ischemia: Evidence for a protective role of serotonin in cerebral ischemia. Brain Res 1993, 630: 10-20.
35. Contreras, P.C., Gray, N.M., Ragan, D.M., Lanthorn, T.H. BMY-14802 protects against ischemia-induced neuronal damage in the gerbil. Life Sci 1992, 51: 1145-9.
36. 2 receptor antagonists. Eur J Pharmacol 1992, 229: 21-9.
37. 1A agonist ipsapirone. The Neurobiology of Stress, a Satellite Symposium to the Meeting of European Neuroscientists (Sept 8-9, Groningen, The Netherlands) 1995, Abst 41.
38. 1A receptors in anxiety. In: New Concepts in Anxiety, M. Briley and S.E. File (Eds.), MacMillan Press, London, 1991, 94-129.
39. Forster, E.A., Cliffe, I.A., Bill, D.J. et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist WAY-100635. Eur J Pharmacol 1995, 281: 81-8.
40. 1A Receptors in Depression and Anxiety, S.M. Stahl, M. Gastpar, J.M. Keppel Hesselink and J. Traber (Eds.), Raven Press, New York, 1992, 55-81.
41. Bederson, J.B., Pitts, L.H., Tsuji, M. et al. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986, 17: 472-6.
42. Koizumi, J., Yoshida, Y., Nakazawa, T., Ooneda, G. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986, 8: 1-8.
43. Nagasawa, H., Kogure, K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 1989, 20: 1037-43.
44. Zhao, Q., Smith, M.-L., Siesjö, B.K. The omega-conopeptide SNX-111, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischemia. Acta Physiol Scand 1994, 150: 459-61.
45. Miller, J.D., Bullock, R., Graham, D.I. et al. Ischemic brain damage in a model of acute subdural hematoma. Neurosurgery 1990, 27: 433-9.
46. 1A agonist, on ACTH and PRL secretion in the rat. Neuroendocrinology 1995, 61: 159-66.
47. Meyer, U.A. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994, 46: 409-15.